RETRACTED: Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapyVector-borne infectionsA defective herpes simplex virus vector system for gene delivery into the brain: comparison with alternative gene delivery systems and usefulness for gene therapy.A dietary risk assessment of the pyrethroid insecticide resmethrin associated with its use for West Nile Virus mosquito vector control in California.A gene therapy approach to treat demyelinating diseases using non-replicative herpetic vectors engineered to produce cytokines.A review of Rocky Mountain spotted fever (tick-borne typhus), its agent, and its tick vectors in the United StatesA review of the vector management methods to prevent and control outbreaks of West Nile virus infection and the challenge for EuropeA review of trends in the distribution of vector-borne diseases: is international trade contributing to their spread?A review on disease vectors breeding in rice fields in tropical Asia and research needsA safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.Acoustic communication in insect disease vectorsAddressing vulnerability, building resilience: community-based adaptation to vector-borne diseases in the context of global change.Adeno-associated viral vectors for Parkinson's diseaseAdeno-associated viral vectors for retinal gene transfer and treatment of retinal diseasesAdeno-associated virus-based vectors in gene therapyAdeno-associated virus-vectored gene therapy for retinal diseaseAdeno-associated virus and lentivirus vectors: a refined toolkit for the central nervous systemAdeno-associated virus and other potential vectors for angiostatin and endostatin gene therapy.Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspectiveAdeno-associated virus as a gene therapy vector: vector development, production and clinical applications.Adeno-associated virus based vectors as antivirals.Adeno-associated virus integration: virus versus vectorAdeno-associated virus serotypes: vector toolkit for human gene therapyAdeno-associated virus type 2 vector for transduction of hematopoietic cells.Adeno-associated virus: from defective virus to effective vectorAdeno-associated virus vector-based gene therapy for monogenetic metabolic diseases of the liverAdeno-associated virus vector-mediated expression and constitutive secretion of galanin suppresses limbic seizure activityAdeno-associated virus vector-mediated gene delivery to the vasculature and kidney.Adeno-associated virus vector integrationAdeno-associated virus vectors and hematologyAdeno-associated virus vectors and neurological gene therapyAdeno-Associated Virus Vectors and Stem Cells: Friends or Foes?Adeno-associated virus vectors for gene therapy of neurodegenerative disorders.Adeno-associated virus vectors for gene therapy of the hematopoietic system.Adeno-associated virus vectors for gene therapy.Adeno-associated virus vectors for gene therapy: more pros than cons?Adeno-associated virus vectors for gene transfer into erythroid cells.Adeno-associated virus vectors for gene transfer to the brain.Adeno-associated virus vectors for therapeutic gene transferAdeno-associated virus vectors in clinical trials
about
label
Generic instance
@en